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MicroRNA-372 (miR-372) acts as either an oncogenic miRNA or an anti-oncomiR in various human malignancies.
However, its roles in gliomas have not been elucidated. To address this problem, we here detected miR-372
expression in human gliomas and non-neoplastic brain tissues by real-time quantitative RT-PCR assay. The
association of miR-372 expression with clinicopathological factors or prognosis of glioma patients was also
statistically analyzed. As the results, miR-372 expression levels were significantly upregulated in glioma tissues
compared to the corresponding non-neoplastic brain tissues (P<0.001). In addition, the high miR-372 expression
was significantly associated with the advanced pathological grade (P=0.008) and the low Karnofsky performance
score (KPS) of glioma patients (P=0.01). Moreover, the overall survival of patients with high miR-372 expression was
dramatically shorter than those with low miR-372 expression (P<0.001). Furthermore, multivariate Cox regression
analysis indicated that miR-372 expression was an independent prognostic factor for glioma patients (P=0.008).
More importantly, subgroup analyses according to tumor pathological grade revealed that the cumulative overall
survival of glioma patients with advanced pathological grades was significantly worse for high miR-372 expression
group than for low miR-372 expression group (P<0.001), but no significant difference was found for patients with
low pathological grades (P=0.08). Taken together, these data offer the convincing evidence for the first time that
miR-372 may act as an oncogenic miRNA in gliomas and represent a potential regulator of aggressive development
and a candidate prognostic marker for this malignancy, especially for advanced tumors with high pathological
grades.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1707761328850011
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Human gliomas are a heterogeneous group of primary
intracranial tumors for both children and adults [1]. The
entities are distinguished based on morphological cri-
teria by histological analysis and presumed cell of origin.
According to the World Health Organization (WHO)
classification which is based on histomorphological cri-
teria, human gliomas includes well-differentiated low
grade astrocytomas [World Health Organization (WHO)
grade I~II], anaplastic astrocytomas (WHO grade III)* Correspondence: heshimingbrain@yahoo.com.cn; gguodong@fmmu.edu.cn
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reproduction in any medium, provided the orand glioblastoma multiforme (GBM, WHO grade IV)
[2]. Despite great progress in therapeutic technologies,
such as surgery, radiotherapy, photodynamic therapy,
and chemotherapy, the clinical outcome of patients with
gliomas remains poor, with a lower than 3% 5-year
survival rate for patients with GBM [3]. Although the
WHO classification can reflect the anticipated malig-
nancy of the tumor and serve as a criterion to predict
the clinical outcome of patients, recent studies have
indicated that histomorphological criteria alone may not
be sufficient to estimate the prognosis [2,4-8]. For
example, Curran et al. [9] demonstrated that the median
survival time of patients with high-grade gliomas range
from 5 to 59 months and some patients with low-grade
tumors also present poor outcome. Therefore, tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathological features of 128 patients with
gliomas
Features WHO I WHO II WHO III WHO IV
Case No. 18 14 38 58
Mean age (year) 38.6 45.9 43.1 44.2
Gender
Male 12 6 25 33
Female 6 8 13 25
KPS
>80 15 11 9 15
<80 3 3 29 43
Surgery
Gross total resection 18 14 28 38
Partial resection 0 0 9 15
Biopsy 0 0 1 5
Adjuvant treatment
Radiotherapy 0 0 30 12
Chemotherapy 0 1 0 6
Radiotherapy and
Chemotherapy combination
0 0 5 28
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to overcome some of these limitations.
MicroRNAs (miRNAs) are a recently discovered class
of short non-coding endogenous RNA molecules that
have a wide impact on the regulation of multiple target
genes’ expression post-transcriptionally [10]. At first,
miRNAs are transcribed by RNA polymerase II to yield
long transcripts known as pri-miRNAs, which are pro-
cessed to pre-miRNAs by the RNase III enzyme Drosha
in the nucleus; then, the pre-miRNAs are exported to
the cytoplasm by exportin-5 and subsequently converted
to mature duplex miRNAs by another RNase III enzyme,
Dicer; after that, mature miRNAs regulate their targets
by direct cleavage of the mRNA or by inhibition of pro-
tein synthesis, according to the degree of complementa-
rities with their targets’ 30UTR regions [11,12]. With the
use of sophisticated techniques and screening tools,
miRNAs have been demonstrated to be involved in
multiple cellular processes, including development, cell
proliferation and differentiation, stem cell maintenance,
epithelial- mesenchymal transition, apoptosis and me-
tabolism [13,14]. miRNAs also play important roles in a
wide variety of physiological and pathological processes
involved in tumorigenesis and tumor progression. De-
pending on their target genes, miRNAs can function
either as oncogenes or tumor suppressors. Accumulating
findings have demonstrated that miRNAs are associated
with glioma formation and growth [15,16]. In the present
study, we focus on miR-372, which has been demonstrated
to act as either an oncogenic miRNA or an anti-oncomiR
in various human malignancies [7,17,18]. However, its
roles in gliomas have not been elucidated. To address this
problem, miR-372 expression in human gliomas and non-
neoplastic brain tissues was measured by real-time quanti-
tative RT-PCR assay. The association of miR-372 with
clinicopathological factors or prognosis of glioma patients
was also statistically analyzed.
Materials and methods
Patients and tissue samples
This study was approved by the Research Ethics Commit-
tee of Tangdu Hospital, Fourth Military Medical Univer-
sity, P. R. China. Written informed consent was obtained
from all of the patients. All specimens were handled and
made anonymous according to the ethical and legal
standards.
One hundred and twenty-eight pairs of glioma and
adjacent non-neoplastic brain tissues resected between
2000 and 2010 were retrieved from the archives of
the Pathology Department of Tangdu Hospital, Fourth
Military Medical University, P. R. China. All the slides
of glioma tissues were re-evaluated according to WHO
classifications [2] by two pathologists, with differences
resolved by careful discussion. A total of 76 males and52 females (1.46:1) were enrolled in this study, and the
median age was 42 years (range, 12–71). Thirty-two of
the 128 gliomas were classified as low-grade [18 pilocytic
astrocytomas (WHO I) and 14 diffuse astrocytomas
(WHO II)], and 96 were classified as high-grade gliomas
[38 anaplasia astrocytomas (WHO III), and 58 primary
glioblastomas (WHO IV)]. None of the patients had
received chemotherapy or radiotherapy prior to surgery.
All the tissues were snap-frozen in liquid nitrogen and
stored at −80°C following surgery for real-time quantita-
tive RT-PCR assay. The clinicopathological features and
the treatment strategies of all the patients were indicated
in Table 1.
Clinical follow-up was available for all patients (median,
16 months; range, 1–148 months). Follow-up information
for all patients was obtained every 3 months by telephone,
at a visit or via a posted questionnaire. During the follow-
up period, overall survival was measured from diagnosis
to death or the last follow-up (5 years). Patients, who died
of diseases not directly related to their gliomas or due to
unexpected events, were excluded from this study.
Real-time quantitative RT-PCR for miRNA
The expression of miR-372 in glioma and adjacent non-
neoplastic brain tissues was measured by real-time
quantitative RT-PCR analysis according to the conven-
tional protocols of Tangdu hospital [19]. Briefly, total
RNA was extracted from frozen samples using Trizol
reagent (Invitrogen, Shanghai, China) according to the
users’ instruction. RNA concentration and purity were
Figure 1 miR-372 expression in 128 pairs of glioma and
adjacent non-neoplatic brain tissues detected by quantitative
real-time polymerase chain reaction (qRT-PCR) analysis. (A)
Expression levels of miR-372 in glioma and paired non-neoplastic
brain tissues. (B) Expression levels of miR-372 in non-neoplastic brain
tissues and glioma tissues with different pathological grades
(Grade I~IV).
Table 2 Association of miR-372 expression in human






High (n, %) Low (n, %)
WHO grade
I 18 2 (11.1) 16 (88.9) 0.008
II 14 2 (14.3) 12 (85.7)
III 38 24 (63.2) 14 (36.8)
IV 58 50 (86.2) 8 (13.8)
Age
<55 52 33 (63.5) 19 (36.5) NS
≥55 76 45 (59.2) 31 (40.8)
Gender
Male 76 45 (59.2) 31 (40.8) NS
Female 52 33 (63.5) 19 (36.5)
KPS
<80 78 56 (71.8) 22 (28.2) 0.01
≥80 50 22 (44.0) 28 (56.0)
Li et al. Diagnostic Pathology 2013, 8:1 Page 3 of 6
http://www.diagnosticpathology.org/content/8/1/1measured using the NanoDrop ND-1000 spectropho-
tometer (NanoDrop Technologies, Houston, TX, USA).
Only the samples with the OD A260/A280 ratio close to
value of 2.0, which indicates that the RNA is pure, were
subsequently analyzed. The miR-372 and RNU6B (as an
internal control)-specific cDNA were synthesized from
total RNA using gene-specific primers according to
the TaqMan MicroRNA assays protocol (Applied Bio-
systems, Foster City, CA, USA). Each reaction included
1×primer probe mix (TaqMan; ABI), 1× universal PCR
master mix (TaqMan; ABI), and 200 ng of cDNA. Rela-
tive quantification of target miRNA expression was
evaluated using the comparative cycle threshold (CT)
method. Each sample was examined in triplicate and
the raw data were presented as the relative quantity of
target miRNA, normalized with respect to RNU6B.
Statistical analysis
All computations were carried out using the software of
SPSS version13.0 for Windows (SPSS Inc, IL, USA).Data were expressed as means±standard deviation (SD).
Paired samples T test has been performed to compare
the expression levels of miR-372 between glioma and
paired non-neoplastic brain tissues. The analysis of vari-
ance (ANOVA) was used to determine the statistical
differences among the groups. A life table was calcu-
lated according to the Kaplan-Meier method. Hazard
ratios for the time-to-event endpoint were estimated
using the multivariate Cox regression analysis in a for-
ward stepwise method to evaluate the effect of multiple
independent prognostic factors on survival outcome.
Differences were considered statistically significant
when p was less than 0.05.Results
miR-372 upregulation in human glioma tissues
MiR-372 expression was detected in 128 pairs of glioma
and adjacent non-neoplastic brain tissues normalized to
RNU6B. As shown in Figure 1A, we found that the ex-
pression of miR-372 was distinctly increased in glioma tis-
sues compared to non-neoplastic brain tissues (mean±SD:
5.2±1.1 vs. 2.4±1.1, P<0.001). In addition, miR-372 ex-
pression in high-grade (III-IV; 5.6±1.0) and low-grade
(I-II; 3.9±0.4) gliomas were both significantly higher
than that in non-neoplastic brain tissues (2.4±1.1;
P<0.001 and 0.001, respectively, Figure 1B). There was
also a significant difference in miR-372 expression be-
tween high-grade (III-IV) and low -grade (I-II) glioma
tissue specimens (P=0.001, Figure 1B).
Figure 2 Kaplan-Meier survival curves for glioma patients with high or low expression of miR-372. (A) The 5-year overall survival rate of
all 128 glioma patients with high or low miR-372 expression; (B) The 5-year overall survival rate of 78 glioma patients with advanced pathological
grades (Grade III~IV) in high or low miR-372 expression group; (C) The 5-year overall survival rate of 50 glioma patients with low pathological
grades (Grade I~II) in high or low miR-372 expression group.
Table 3 Cox multivariate analysis
Parameter Risk ratio 95% confidence
interval
P
Age 0.89 0.58-1.65 0.71
Gender 1.02 0.66-1.83 0.33
KPS 1.99 1.28-2.95 0.06
Extent of resection 1.29 0.89-2.13 0.11
Type of adjuvant treatment 1.37 1.02-2.24 0.11
miR-372 expression 4.37 2.11-8.93 0.008
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clinicopathological features of gliomas
We then analyzed the association between miR-372 ex-
pression and clinicopathological parameters in gliomas.
Glioma tissues expressing miR-372 at levels less than the
median expression level (4.9) were assigned to the low
expression group (mean expression value 4.3, n=50), and
those samples with expression above the median value
were assigned to the high expression group (mean ex-
pression value 5.8, n=78). The high level of miR-372
expression was significantly more common in glioma tis-
sues with advanced pathologic grade than those with
low pathologic grade (P=0.008, Table 2). A significant
relationship was also observed between miR-372 expres-
sion and the KPS. miR-372 upregulation occurred more
frequently in tumors with low KPS than those with high
KPS (P=0.01). No significant association was found
between miR-372 expression and gender or age at
diagnosis.
Relationship of miR-372 expression with overall survival
in patients with gliomas
In order to investigate the relationship between miR-372
expression and clinical outcome in gliomas, the clinical
information of the glioma patients in miR-372-high or
-low groups was reviewed. During the follow-up period,
100 of 128 glioma patients (78.1%) had died [72 (92.3%)
from the miR-372-high group and 28 (56.0%) from the
miR-372-low group]. As determined by the log-rank test,
the survival rate of patients with high miR-372 expres-
sion was significantly lower than those with low miR-
372 expression (P<0.001; Figure 2). In multivariate
analysis, Cox proportional hazards model involving the
expression level of miR-372 protein and various clinicalparameters identified miR-372 upregulation (P=0.008) as
an independent prognostic factor for glioma patients.
Statistical values of the expression of miR-372 and other
clinical parameters derived from Cox stepwise propor-
tional hazards model were indicated in Table 3.
More importantly, subgroup analyses according to
tumor pathological grade revealed that the cumulative
overall survival of glioma patients with advanced patho-
logical grade (Grade III~IV) was significantly worse for
high miR-372 expression group than for low miR-372
expression group (P<0.001, Figure 2B), but no significant
difference was found for patients with low pathological
grades (Grade I~II, P=0.08, Figure 2C).
Discussion
Biomarker screening is an emerging field for neuro-
oncology. Especially for gliomas, considerable progresses
have been made in identifying, characterizing, and ap-
plying molecular markers. In the present study, we initially
found that miR-372 was upregulated in human glioma
tissues compared with non-neoplastic brain tissues. Then,
the increased expression of miR-372 in glioma tissues was
significantly correlated with advanced tumor progression
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Kaplan-Meier analysis revealed that glioma patients with
high miR-372 expression tend to have poorer overall sur-
vival. In addition, the multivariate analysis clearly demon-
strated that high miR-372 expression was a statistically
significant risk factor affecting overall survival in glioma
patients, suggesting that miR-372 upregulation in gliomas
is not only in a grade-dependent fashion, it is also a pre-
dictor of overall survival. Finally, subgroup analyses
showed the significant prognostic value of miR-372 upre-
gulation for glioma patients especially for those with
advanced pathological grade.
MiR-372, together with miR-371a, miR-371b and miR-
373, belongs to miR-371~373 cluster which has been
demonstrated to play important roles in tumorigenesis
and tumor progression [20]. Among these members,
miR-372 may act as either an oncogenic miRNA or an
anti-oncomiR in various human malignancies. It can
enhance cell proliferation, stimulate cell cycle progres-
sion, and decrease apoptosis of tumor cells in many
types of cancer. For example, Cho et al. [17] revealed
that miR-372 plays an oncogenic role through down-
regulation of the tumor suppressor gene LATS2, which
accelerated growth and survival of gastric cancer cells;
Yamashita et al. [21] indicated that the increased expres-
sion of miR-372 in colon cancer was an independent
prognostic factor and was associated with synchronous
liver metastasis; Voorhoeve et al. [14] demonstrated that
miR-372 could enhance cell proliferation, stimulate cell
cycle progression, or decrease apoptosis in testicular
germ cell tumors. Consistent with these previous studies,
our data also found the upregulation of miR-372 in
glioma tissues compared with paired adjacent non-
neoplastic brain tissues. In addition, the aberrant expres-
sion of miR-372 was associated with advanced patho-
logical grades and low KPS of glioma patients, indicating
that this miRNA may be involved in the development of
human gliomas. By contrast, accumulating studies
showed the tumor suppressive roles of miR-372 in many
cancers. For example, Tian et al. [22] found the down-
regulation of miR-372 in cervical carcinoma tissues as
compared with adjacent normal cervical tissues. The
authors demonstrated that its anti-oncogenic role might
be through control of cell growth and cell cycle progres-
sion by down-regulating the cell cycle genes CDK2 and
cyclin A1. These findings suggest that the different ex-
pression patterns and involvement of miR-372 in various
cancers may depend on the roles of its target genes.
Our findings that miR-372 upregulation was associated
with aggressive tumor progression mentioned above
prompt us to investigate its possible prognostic value in
glioma patients. According to the univariate and multi-
variate analyses, we identified miR-372 upregulation as
an independent predictor for short overall survival ofglioma patients, which was consistent with the findings
of Yamashita et al. [21] in colon cancer. Interestingly,
our subgroup analyses further suggested that miR-372
may act as a significant prognostic factor for glioma
patients with high pathological grades (III~IV), but not
for those with low pathological grades (I~II).Conclusion
In conclusion, our data offer the convincing evidence for
the first time that miR-372 may act as an oncogenic
miRNA in gliomas and represent a potential regulator of
aggressive development and a candidate prognostic mar-
ker for this malignancy, especially for advanced tumors
with high pathological grades. Further elucidation of the
mechanism by which the oncogenic roles of miR-372 in
gliomas are thwarted is worth to be done.
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